Forte Biosciences (FBRX) Accounts Payables (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Accounts Payables data on file, last reported at $13.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $13.1 million, up 160.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (up 160.48% YoY), and the FY2025 annual result was $10.0 million, up 104.73% from the prior year.
• Accounts Payables improved to $13.1 million in Q1 2026 per FBRX's latest filing, from $10.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $13.1 million in Q1 2026 and troughed at $576000.0 in Q1 2022.
• A 5-year average of $4.2 million and a median of $4.9 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables slumped 48.88% in 2022, then jumped 349.54% in 2023.
• A 5-year view of Accounts Payables shows it stood at $1.2 million in 2022, then increased by 23.5% to $1.4 million in 2023, then jumped by 242.63% to $4.9 million in 2024, then jumped by 104.73% to $10.0 million in 2025, then soared by 30.98% to $13.1 million in 2026.
• Business Quant data shows FBRX's Accounts Payables at $13.1 million in Q1 2026, $10.0 million in Q4 2025, and $5.5 million in Q3 2025.